ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0742

Patient Factors Influencing Recruitment in a Telemedicine Randomized Clinical Trial

Lesley Jackson1, Kiara Aaron1, Jinoos Yazdany2, Sarah Goglin3, Diana Perez4, David Chae5, Mary Margaretten2, Faith Mugeta1, Norma Techarukpong1, Ellen McNeeley1, Gary Cutter1, kenneth saag1 and Maria Danila1, 1University of Alabama at Birmingham, Birmingham, AL, 2UCSF, San Francisco, CA, 3University of California San Francisco, San Francisco, CA, 4UCSF, Houston, TX, 5Tulane University School of Public Health and Tropical Medicine, New Orleans, LA

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Health Services Research Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: In the COVID era, telemedicine has assumed an increasing role in rheumatology care, yet questions remain about its comparative effectiveness and satisfaction relative to in-person care, which we are studying in a randomized clinical trial (RCT) entitled EVOLVE (NCT04704544). Conducting clinical trials on telemedicine are limited by possible participation bias. We sought to describe and compare the characteristics of patients who enrolled in EVOLVE vs. those who were contacted but did not enroll at one academic medical center in the Deep South.

Methods: We used the rheumatology clinic appointment list to identify established patients age ≥18 years with a rheumatic disease with at least 2 clinic visits including ≥1 in-person visit in the last 18 months. Research assistants reviewed electronic health records of potentially eligible patients and contacted them by phone to assess acceptability of participating in either a telemedicine or in-person visit with their rheumatologist. Patients without equipoise for either visit type were excluded. We used descriptive statistics and reported mean (SD), median (interquartile range) or frequency (percentage) to summarize patient characteristics. In addition to age, sex, and race/ethnicity, we analyzed the association of covariates with enrollment status including socioeconomic disadvantage (Area Deprivation Index), distance from a participant’s primary residence to clinic, and medication use. Variables with p≤0.3 in the univariable analysis or of biologic significance (e.g., sex and race/ethnicity) were considered in a multivariable logistic regression model to examine factors associated with RCT enrollment. This project was approved by the UAB Institutional Review Board with a waiver of informed consent (IRB-300006553).

Results: From August 2021 to May 2022, 885 patients were contacted by phone. Of these, 331 persons, mean (SD) age 56.8 (15.3) years, 17% men, 34.7% non-Hispanic Blacks were not enrolled in the study (Table 1). Reasons for exclusion included patient preference for a visit type, travel distance to clinic, not wanting to be surveyed post-clinic visit, reported need for an in-office procedure, among others. Those who were enrolled vs. not were well balanced by sex, race/ethnicity, and level of socioeconomic disadvantage. In multiple regression analysis in which the outcome was study enrollment, every 10 years of increased age was associated with a 12.3% decrease in chance of enrolling (p=0.01) and every 25 miles of increased distance from clinic was associated with a 8.9% decrease in chance of enrolling (p=0.04) in the RCT.

Conclusion: We found that patients who enrolled in the EVOLVE RCT of telemedicine vs. in-person visits were younger and lived closer to the rheumatology clinic. Our findings suggest that older individuals and those living further from our academic medical center may be underrepresented in this telemedicine trial, however enrollment is ongoing. This study also illustrates good generalizability to other groups, such as those characterized by sex, race/ ethnicity, and area deprivation index. These data will inform recruitment efforts for clinical trials involving telemedicine.

Supporting image 1

* Beta estimates were multiplied by 10 for age and 25 for distance from clinic when we calculated the corresponding change in chance of enrolling.
§Area Deprivation Index State decile from 1 (least disadvantaged) to 10 (most disadvantaged); ‖National percentile from 1 (least disadvantaged) to 100 (most disadvantaged), missing for 120 participants. Race/ethnicity “Other” includes Hispanic/Latino, Asian, Native American, American Indian or Alaska Native, or not listed. Other medications include allopurinol, colchicine, IVIG, and anti-fibrotics (nintedanib, pirfenidone). Other medications were not included in the multivariable model due to small sample size.


Disclosures: L. Jackson, BHOF; K. Aaron, None; J. Yazdany, AstraZeneca, Gilead, Bristol-Myers Squibb(BMS), Aurinia, Astra Zeneca, Pfizer; S. Goglin, None; D. Perez, None; D. Chae, None; M. Margaretten, None; F. Mugeta, None; N. Techarukpong, None; E. McNeeley, None; G. Cutter, AI Therapeutics, AMO Pharma., Astra-Zeneca,, Avexis Pharmaceuticals, Biolinerx, Brainstorm Cell Therapeutics, Bristol Meyers Squibb/Celgene, CSL Behring,, Galmed Pharmaceuticals, Green Valley Pharma, Horizon Pharmaceuticals, mmunic, Mapi Pharmaceuticals LTD, Merck, Mitsubishi Tanabe Pharma Holdings, Opko Biologics, Prothena Biosciences, Novartis, Regeneron,, Sanofi-Aventis, Reata Pharmaceuticals, Alexion, Antisense Therapeutics, Biogen, Clinical Trial Solutions LLC, Genzyme, Genentech, GW Pharmaceuticals/Jazz, Klein-Buendel Incorporated, Merck/Serono, Osmotica Pharmaceuticals, Perception Neurosciences, Protalix Biotherapeutics,, Recursion/Cerexis Pharmaceuticals, Roche, SAB Biotherapeutics; k. saag, Horizon Therapeutics, SOBI, Shanton, AbbVie/Abbott; M. Danila, UCB, Pfizer.

To cite this abstract in AMA style:

Jackson L, Aaron K, Yazdany J, Goglin S, Perez D, Chae D, Margaretten M, Mugeta F, Techarukpong N, McNeeley E, Cutter G, saag k, Danila M. Patient Factors Influencing Recruitment in a Telemedicine Randomized Clinical Trial [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/patient-factors-influencing-recruitment-in-a-telemedicine-randomized-clinical-trial/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-factors-influencing-recruitment-in-a-telemedicine-randomized-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology